Skip to main content

Month: July 2024

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, and SGN Nanopharma, today announced that the companies have entered into a collaboration agreement to develop a treatment for chronic dry eye disease. Under the terms of the agreement, the companies will work to develop SGN’s Micellar Nanoparticle Platform (MNP) platform-based cyclosporine formulation for use with Eyenovia’s Optejet® dispenser. The companies are currently validating the novel drug-device combination product’s manufacturability to support clinical testing and will then schedule a consultation meeting with the FDA...

Continue reading

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw continued progress against core development goals for each of the components of our platform,” said Sujal Patel, CEO of Nautilus. “We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to view as one of the most significant untapped opportunities in biological science.” Second Quarter 2024 Financial Results Operating expenses were $20.8...

Continue reading

IPG Photonics Announces Second Quarter 2024 Financial Results

Prioritizing Investment in Innovation Pipeline While Optimizing Business for Cash Generation MARLBOROUGH, Mass., July 30, 2024 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the second quarter ended June 30, 2024.  Three Months Ended June 30,           Six Months Ended June 30,        (In millions, except per share data and percentages)   2024       2023       Change       2024       2023       Change  Revenue $ 257.6     $ 340.0       (24 )%   $ 509.7     $ 687.1       (26 )%Gross margin   37.3 %     43.4 %             38.0 %     42.9 %        Operating income $ 12.0     $ 72.1       (83 )%   $ 31.1     $ 147.5       (79 )%Operating margin   4.7 %     21.2 %             6.1 %     21.5 %        Net income attributable to IPG Photonics Corporation $ 20.2     $ 62.3       (68 )%   $ 44.3     $ 122.5       (64 )%Earnings...

Continue reading

ITW Reports Second Quarter 2024 Results

Revenue of $4.0 billion, a decrease of 1% with flat organic growth Operating income of $1.05 billion, an increase of 4.5% Operating margin of 26.2%, an increase of 140 bps as enterprise initiatives contributed 140 bps GAAP EPS of $2.54, an increase of 2%; Excl. a one-time 2023 tax item, EPS increased 5% Narrowing full year GAAP EPS guidance to a range of $10.30 to $10.40 per shareGLENVIEW, Ill., July 30, 2024 (GLOBE NEWSWIRE) — Illinois Tool Works Inc. (NYSE: ITW) today reported its second quarter 2024 results and updated guidance for full-year 2024. “While the demand environment continued to moderate across our portfolio, we delivered a solid quarter with strong operational execution and profitability,” said Christopher A. O’Herlihy, President and Chief Executive Officer. “Our ability to overcome near-term macro challenges...

Continue reading

Amplify ETFs Declares July Income Distributions for its ETFs

CHICAGO, July 30, 2024 (GLOBE NEWSWIRE) — Amplify ETFs announces July income distributions for its ETFs.ETF Name Ticker Amount per Share Ex-Date Record Date Payable DateAmplify High Income ETF YYY $0.12000 7/30/2024 7/30/2024 7/31/2024Amplify CWP Enhanced Dividend Income ETF DIVO $0.15843 7/30/2024 7/30/2024 7/31/2024Amplify Natural Resources Dividend Income ETF NDIV $0.13369 7/30/2024 7/30/2024 7/31/2024Amplify CWP International Enhanced Dividend Income ETF IDVO $0.15360 7/30/2024 7/30/2024 7/31/2024Amplify Cash Flow Dividend Leaders ETF COWS $0.03647 7/30/2024 7/30/2024 7/31/2024Amplify Cash Flow High Income ETF HCOW $0.17513 7/30/2024 7/30/2024 7/31/2024Amplify Samsung SOFR ETF SOF $0.44767 7/30/2024 7/30/2024 7/31/2024About Amplify ETFsAmplify ETFs, sponsored by Amplify Investments, has over $9 billion...

Continue reading

Defiance ETFs Announces Monthly Distributions on $QQQY (71.41%), $JEPY (42.47%), $IWMY (73.90%), $SPYT (20.03%), $USOY (51.14%), and QQQT (20.01%)

Defiance ETFs announces monthly distributionsDefiance ETFs Announces Monthly Distributions on $QQQY (71.41%), $JEPY (42.47%), $IWMY (73.90%), $SPYT (20.03%), $USOY (51.14%), and QQQT (20.01%).MIAMI, July 30, 2024 (GLOBE NEWSWIRE) — Defiance ETFs, a leader in thematic and income ETFs, is proud to announce monthly distributions for the QQQY – Defiance Nasdaq-100 Enhanced Options Income ETF, JEPY – Defiance S&P 500 Enhanced Options Income ETF, IWMY – Defiance R2000 Enhanced Options Income ETF, SPYT – Defiance S&P 500 Target Income ETF, USOY – Defiance Oil Enhanced Options Income ETF, QQQT – Defiance Nasdaq 100 Income Target ETF. Distribution as of 07/30/2024ETFTicker Distributionper Share DistributionRate * Ex-Date RecordDate PaymentDateQQQY $0.8342 71.41% 07/31/2024 07/31/2024 08/02/2024JEPY $0.5582 42.47% 07/31/2024 07/31/2024 08/02/2024IWMY $0.8807 73.90% 07/31/2024 07/31/2024 08/02/2024SPYT $0.3302 20.03% 07/31/2024 07/31/2024 08/02/2024USOY $0.7700 51.14% 07/31/2024 07/31/2024 08/02/2024QQQT $0.3175 20.01% 07/31/2024 07/31/2024 08/02/2024As...

Continue reading

Novacium’s Silicon-Based Batteries with GEN3 Anode Material Surpass 4,000 mAh

World-Class Results: This Milestone adds Novacium to the List of Only 3 Companies with Most Energy-Dense 18650 Batteries MONTREAL, July 30, 2024 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company specializing in green engineering of silica and silicon-based materials is pleased to announce the latest significant battery milestones achieved by its France-based affiliate, NOVACIUM SAS (“Novacium”). This announcement involves the latest batch of batteries, made with a blend of graphite and Novacium’s partially optimized third-generation (GEN3) advanced silicon-based anode material, has surpassed the average capacity of 4,030 milliampere-hours (mAh) [1]. This result is close to the actual world record for 18650 batteries of 4,095 mAh [2]. However, validation...

Continue reading

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone. bioavailability/bioequivalence (‘BA/BE’) clinical trial assessed the pharmacokinetics and tolerability of IHL-42X consistent with FDA development plan. Analysis of data underway, however, no serious adverse events were reported. Phase 2/3 FDA IND-enabling RePOSA clinical trial continues after dosing commenced in May 2024.NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed...

Continue reading

Watsco Reports Record Sales, Enhanced Operating Efficiency and Strong Cash Flow During Second Quarter

Continued Customer Adoption of Industry-Leading Technologies Helps Drive Share Gains; Debt-Free Balance Sheet Supports Long-Term Investment and Growth MIAMI, July 30, 2024 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced its operating results for the second quarter and six-month period ended June 30, 2024. Commentary was also provided on business trends, growth opportunities, technology innovation and its financial position. Watsco is the largest distributor in the highly fragmented $64 billion North American HVAC/R marketplace, with more than $7 billion in annual sales and nearly 700 locations in the U.S., Canada, and Latin America. Watsco estimates that over 375,000 owner-operators, technicians and installers visit, call or digitally engage with one of its locations each year to get information, obtain technical support...

Continue reading

VitalHub Corp. to Acquire MedCurrent Corporation

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) — VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has signed a definitive agreement (the “Definitive Agreement”) to acquire MedCurrent Corporation and its subsidiaries (“MedCurrent”), by way of a court-approved plan of arrangement under the provisions of the Business Corporations Act (Ontario) (the “Transaction”). MedCurrent is a physician-founded Clinical Decision Support (CDS) company focused on improving the quality of care and managing health system costs through its innovative and scalable solution, OrderWise. OrderWise enhances the clinical decision-making process within real-time to determine the appropriateness of a test using evidence-based guidelines and artificial intelligence (AI) integrated at the point of care. To date, the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.